BIOCRYST PHARMACEUTICALS, INC. Repayments of Secured Debt
BIOCRYST PHARMACEUTICALS, INC. (BCRX) reported Repayments of Secured Debt of $0 for the 12-month period ending 2024-12-31, per its 10-K filed 2025-02-25.
Financial Statements › Cash Flow › Financing Activities
us-gaap:RepaymentsOfSecuredDebt · last filed 2025-02-25
- BIOCRYST PHARMACEUTICALS, INC. repayments of secured debt for the quarter ending 2024-12-31 was $0.00.
- BIOCRYST PHARMACEUTICALS, INC. repayments of secured debt for the quarter ending 2024-09-30 was $0.00.
- BIOCRYST PHARMACEUTICALS, INC. repayments of secured debt for the quarter ending 2023-12-31 was $0.00.
- BIOCRYST PHARMACEUTICALS, INC. repayments of secured debt for the quarter ending 2023-09-30 was $0.00.
- BIOCRYST PHARMACEUTICALS, INC. repayments of secured debt for fiscal 2024 was $0.00, a 100.00% decline from fiscal 2023.
- BIOCRYST PHARMACEUTICALS, INC. repayments of secured debt for fiscal 2023 was $240.45M.
- BIOCRYST PHARMACEUTICALS, INC. repayments of secured debt for fiscal 2022 was $0.00.
- BIOCRYST PHARMACEUTICALS, INC. repayments of secured debt for fiscal 2021 was $0.00.
| Period end | Repayments of Secured Debt 3 month | Repayments of Secured Debt 6 month | Repayments of Secured Debt 9 month | Repayments of Secured Debt 12 month |
|---|---|---|---|---|
| 2024-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-25 | $0.00 derived: sum of 2 quarters · filed 2025-02-25 | $0.00 10-K · filed 2025-02-25 | |
| 2024-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-05 | $0.00 10-Q · filed 2024-11-05 | ||
| 2024-06-30 | $0.00 10-Q · filed 2024-08-06 | |||
| 2023-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-25 | $0.00 derived: sum of 2 quarters · filed 2025-02-25 | $240.45M 10-K · filed 2025-02-25 | |
| 2023-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-05 | $240.45M 10-Q · filed 2024-11-05 | ||
| 2023-06-30 | $240.45M 10-Q · filed 2024-08-06 | |||
| 2022-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-25 | $0.00 derived: sum of 2 quarters · filed 2025-02-25 | $0.00 10-K · filed 2025-02-25 | |
| 2022-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-08 | $0.00 10-Q · filed 2023-11-08 | ||
| 2022-06-30 | $0.00 10-Q · filed 2023-08-07 | |||
| 2021-12-31 | $0.00 10-K · filed 2024-02-27 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ADMA BIOLOGICS, INC. (ADMA) | United States | $2.131B | 11.16 |
| Kodiak Sciences Inc. (KOD) | United States | $2.090B | -10.12 |
| RECURSION PHARMACEUTICALS, INC. (RXRX) | United States | $2.080B | -3.78 |
| Vericel Corp (VCEL) | United States | $2.011B | 93.97 |
| Greenland Mines Ltd (GRML) | United States | $2.362B | |
| Vir Biotechnology, Inc. (VIR) | United States | $1.814B | -6.85 |
| Beam Therapeutics Inc. (BEAM) | United States | $2.549B | -41.51 |
| NOVAVAX INC (NVAX) | United States | $1.748B | -6.26 |
| Hemab Therapeutics Holdings, Inc. (COAG) | United States | $1.672B | |
| Immunocore Holdings plc (IMCR) | $1.613B | -90.43 |